Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

V-ATPase C2 Inhibitors

V-ATPase C2, or the C subunit of vacuolar-type H+-ATPase, plays a critical role in the acidification of intracellular compartments, such as endosomes, lysosomes, and the Golgi apparatus. This enzyme is part of the proton pump complex that transfers protons across biological membranes, which is essential for various cellular processes including protein sorting, zymogen activation, and the degradation of macromolecules. The acidification process driven by V-ATPase C2 is also crucial for maintaining an acidic environment in osteoclasts, which is necessary for bone resorption. Thus, V-ATPase C2 is a key component in both normal cellular functions and specialized functions in certain cell types. The activity of V-ATPase C2 ensures that cellular pH is properly regulated, which affects many biochemical pathways and cellular functions that depend on specific pH conditions.

The inhibition of V-ATPase C2 can lead to significant changes in cellular physiology by disrupting the acid-base balance within cellular organelles, impacting processes like receptor-mediated endocytosis, protein degradation, and ion storage. Mechanisms of inhibition typically involve targeting the functionality of the V-ATPase complex, either by directly interfering with the assembly or stability of the complex, or by affecting its proton pumping capability. Small molecule inhibitors, for instance, can bind to the V-ATPase C2 subunit or associated components, blocking the proton channel or altering the conformation of the enzyme complex so that it becomes less efficient or entirely inactive. Genetic approaches such as RNA interference can also be used to reduce the expression of V-ATPase C2, thereby decreasing the overall activity of the proton pump. These inhibitory strategies affect the enzyme's ability to maintain pH homeostasis within organelles, potentially leading to alterations in cellular trafficking, signaling, and metabolism. The inhibition of V-ATPase C2, therefore, offers a window into understanding the essential roles of cellular pH in health and disease, providing insights into a fundamental aspect of cell biology.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Concanamycin A

80890-47-7sc-202111
sc-202111A
sc-202111B
sc-202111C
50 µg
200 µg
1 mg
5 mg
$66.00
$167.00
$673.00
$2601.00
109
(2)

Selective V-ATPase inhibitor that directly interacts with the V0 subunit, disrupting proton translocation and subsequently impeding V-ATPase C2 functionality.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$98.00
$255.00
$765.00
$1457.00
280
(6)

Binds the V0 c-subunit of V-ATPase, inhibiting proton pumping and thus causing functional disruption of V-ATPase C2.

Omeprazole

73590-58-6sc-202265
50 mg
$67.00
4
(1)

Proton pump inhibitor that reduces H+ ion concentration, indirectly attenuating V-ATPase C2 activity by diminishing substrate availability.

Indomethacin

53-86-1sc-200503
sc-200503A
1 g
5 g
$29.00
$38.00
18
(1)

Inhibits cyclooxygenase pathways, decreasing the need for proton pumping and thus reducing V-ATPase C2 activity.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

p38 MAPK inhibitor that alters intracellular signaling, leading to reduced translation and synthesis of V-ATPase C2.

PD173074

219580-11-7sc-202610
sc-202610A
sc-202610B
1 mg
5 mg
50 mg
$47.00
$143.00
$680.00
16
(1)

FGFR inhibitor that downregulates the MAPK pathway, causing a subsequent decrease in V-ATPase C2 expression.

ML-9

105637-50-1sc-200519
sc-200519A
sc-200519B
sc-200519C
10 mg
50 mg
100 mg
250 mg
$112.00
$449.00
$673.00
$1224.00
2
(1)

MLCK inhibitor that reduces calcium-mediated intracellular signaling, indirectly affecting V-ATPase C2 activity.

KN-93

139298-40-1sc-202199
1 mg
$182.00
25
(1)

CaMKII inhibitor that modulates calcium signaling, indirectly impacting the need for V-ATPase C2 in vesicle acidification.

Roscovitine

186692-46-6sc-24002
sc-24002A
1 mg
5 mg
$94.00
$265.00
42
(2)

CDK inhibitor that interferes with cell cycle progression, consequently decreasing the need for V-ATPase C2 function.

H-89 dihydrochloride

130964-39-5sc-3537
sc-3537A
1 mg
10 mg
$94.00
$186.00
71
(2)

PKA inhibitor that reduces cAMP levels, thereby lowering V-ATPase C2 activation via cAMP-dependent pathways.